# A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

> **NCT06030076** · — · RECRUITING · sponsor: **Almirall, S.A.** · enrollment: 50 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Tildrakizumab

## Key facts

- **NCT ID:** NCT06030076
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-06
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030076, "A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06030076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*